S12 Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis
Year: 2009
Type: article
Abstract: Session 3. Biology of breast cancer II: Genetics and beyond S5Although the encouraging results observed with the use of chemoprevention in reducing breast cancer incidence in healthy, at-risk women [11], results from breast cancer prevention trials leave several unanswered questions, as well as the efficacy in healthy BRCA1/2 mutation carriers, ER-negative DCIS or prior ER-negative breast cancer who have a high risk of developing an ER-negative tumor: these high risk women represent a potential candidate group for phase I-II chemoprevention trials with novel agents targeting distinct molecular pathways, including EGFR, HER-2, COX-2 and RAR-RXRs [12].
Source: The Breast
Authors: T. Powles, P. Neven, C. Osborne, P. Goss, C. Allred, S. Cummings, K. Wolter, J. Thompson, R. Armstrong, A. LaCroix
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,200
OpenAlex ID: W2023607335